PSUSA/00001317/202503

PSUSA/00001466/202503

Human medicines European public assessment report (EPAR): Usymro, ustekinumab, Date of authorisation: 14/08/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Pylclari, piflufolastat (18F), Date of authorisation: 27/11/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Pegasys, peginterferon alfa-2a, Date of authorisation: 20/06/2002, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Beyonttra, acoramidis, Date of authorisation: 10/02/2025, Revision: 3, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Portela, relfovetmab, Status: Authorised

Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Date of authorisation: 20/06/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Mektovi, binimetinib, Date of authorisation: 20/09/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Braftovi, encorafenib, Date of authorisation: 19/09/2018, Revision: 17, Status: Authorised